Wegovy (semaglutide 2.4 mg) is a prescription-only weight management medicine licensed by the MHRA for adults with obesity or overweight with weight-related comorbidities. Understanding Wegovy cost is essential for patients considering this treatment, as pricing varies significantly between NHS and private routes. Private prescription costs typically range from £150 to £300 per month, with annual expenditure potentially exceeding £2,000 to £3,500. NHS availability remains limited, requiring specialist referral and meeting strict eligibility criteria. This guide examines Wegovy pricing structures, legitimate access routes, and factors to consider when evaluating whether this treatment represents value for your circumstances.

Understanding Wegovy Pricing in the UK

Wegovy (semaglutide 2.4 mg) is a prescription-only medicine licensed by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities. The cost of Wegovy in the UK varies significantly depending on whether you access it through the NHS or via private prescription, and pricing structures differ across pharmacies and online platforms.

Private prescription costs typically range from £150 to £300 per month, depending on the dose and supplier. Wegovy is administered as a once-weekly subcutaneous injection, with treatment starting at a lower dose (0.25 mg) and gradually increasing over 16–20 weeks to the maintenance dose of 2.4 mg. Wegovy is supplied as single-dose prefilled pens, with a monthly supply typically consisting of a pack of 4 pens (one injection per week). The total annual cost for private patients can therefore exceed £2,000 to £3,500, making it a substantial financial commitment.

NHS availability is currently limited. Following NICE guidance (TA875, March 2023), Wegovy is recommended for weight management in specialist NHS services for adults with at least one weight-related comorbidity and a BMI of ≥35 kg/m² (or lower BMI thresholds, usually reduced by 2.^[2][3]5 kg/m², for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds). NICE recommends treatment for a maximum of 2 years within specialist services, with a review at 6 months to ensure at least 5% weight loss has been achieved.^[2][3]

Patients meeting eligibility criteria may access Wegovy at standard NHS prescription charges (currently £9.90 per item in England, with exemptions available; prescription charges do not apply in Scotland, Wales and Northern Ireland), but availability varies by region and local commissioning arrangements.^[9][10]

Where to Buy Wegovy: NHS vs Private Prescriptions

NHS access to Wegovy requires referral to a specialist weight management service. Your GP cannot directly prescribe Wegovy on the NHS; instead, they must refer you to a tier 3 or tier 4 weight management programme. These services assess eligibility based on NICE criteria, including BMI thresholds, presence of comorbidities (such as type 2 diabetes, hypertension, or obstructive sleep apnoea), and previous weight management attempts. If accepted, treatment is initiated under specialist supervision with regular monitoring and lifestyle support. However, some areas have reported restrictions due to supply constraints, which may affect waiting times for treatment.

Private prescription routes offer faster access but at considerably higher cost. Patients can obtain Wegovy through:

• Private GP consultations – either face-to-face or via telehealth platforms

• Specialist weight management clinics – offering comprehensive assessment and ongoing monitoring

• Regulated online pharmacy services – providing remote consultations with prescribers

All legitimate routes require a clinical assessment by a UK-registered prescriber (doctor, nurse prescriber, or pharmacist prescriber) who will evaluate your medical history, current medications, BMI, and suitability for treatment. Reputable providers conduct thorough assessments including contraindication screening and discussion of potential adverse effects.

Important safety note: Wegovy should never be purchased without a valid prescription. Unregulated sources may supply counterfeit or improperly stored medication, posing serious health risks. Always verify that any online pharmacy is registered with the General Pharmaceutical Council (GPhC) by checking the GPhC online register.^[16] Online clinics providing prescribing services should be registered with the Care Quality Commission (CQC) in England, and all prescribers should be registered with their appropriate regulatory body (GMC, NMC, or GPhC).

Medicine Market Place and Online Pharmacy Options

The term 'medicine market place' typically refers to online platforms connecting patients with regulated healthcare providers and pharmacies. Several legitimate UK-based services offer Wegovy through remote consultation models, but it is essential to distinguish between properly regulated providers and potentially unsafe sources.

Regulated online pharmacies operating legally in the UK must:

• Be registered with the General Pharmaceutical Council (GPhC)

• Display the GPhC registration logo prominently on their website

• Provide access to qualified prescribers for clinical assessment

• Dispense only genuine, licensed medicines from approved wholesalers

• Maintain appropriate cold-chain storage for temperature-sensitive medications like Wegovy

• Offer clinical support and monitoring throughout treatment

Online clinics providing prescribing services should also be registered with the Care Quality Commission (CQC) in England or equivalent regulators in other UK nations.

Reputable platforms typically charge £150–250 per month for Wegovy, which includes the consultation fee, prescription, and medication. Some services offer subscription models with regular follow-up consultations to monitor progress, manage side effects, and adjust treatment as needed.

Price comparison across different providers is advisable, but the cheapest option is not always the safest. Consider factors beyond cost, including:

• Quality of clinical assessment and ongoing support

• Prescriber qualifications and accessibility

• Medication sourcing and storage practices

• Patient reviews and regulatory compliance

• Transparency about total costs (some providers charge separately for consultations and medication)

Red flags indicating potentially unsafe sources include: prices significantly below market rate, no requirement for consultation, inability to verify GPhC and CQC registration, requests for payment via untraceable methods, or suppliers based outside the UK without proper regulatory oversight. The MHRA regularly issues warnings about counterfeit weight-loss medications, making verification of legitimacy paramount.^[14][15]

Factors Affecting Wegovy Cost

Several variables influence the total cost of Wegovy treatment, and understanding these can help patients make informed decisions about accessing this medication.

Dosing schedule significantly impacts cost. Wegovy treatment follows a dose-escalation protocol over 16–20 weeks, starting at 0.25 mg weekly and increasing gradually to the maintenance dose of 2.4 mg, as outlined in the Summary of Product Characteristics. During the initial titration phase, lower-dose pens are used, which may be priced differently. Some providers offer starter packs at reduced rates, whilst others maintain consistent monthly pricing regardless of dose.

Supply and demand dynamics have notably affected Wegovy pricing. Since its UK launch, intermittent supply shortages have occurred due to high global demand for semaglutide products. When supply is constrained, some private providers increase prices or limit new patient enrolments. Novo Nordisk, the manufacturer, has implemented allocation systems to manage supply, which can affect availability and pricing across different channels.

Consultation and monitoring costs vary between providers. Some services include regular follow-up consultations in their monthly fee, whilst others charge separately for initial assessment (£30–100) and subsequent reviews (£20–50 each). Comprehensive weight management programmes offering dietetic support, behavioural counselling, and regular clinical monitoring typically cost more than basic prescription services.

Prescription duration also affects overall expenditure. Some providers issue monthly prescriptions requiring repeated consultations, whilst others may prescribe three-month supplies after initial stabilisation, potentially reducing consultation frequency and associated costs. However, multi-month prescriptions may be limited by supply constraints, clinical monitoring requirements, and cold-chain storage considerations, as Wegovy requires refrigeration.

Geographic location can influence pricing, particularly for in-person consultations at private clinics, which may charge premium rates in major cities. Online services generally offer more consistent national pricing but may have regional variations in delivery charges or service availability.

Is Wegovy Worth the Price? What to Consider

Determining whether Wegovy represents value for money requires careful consideration of clinical effectiveness, personal circumstances, and alternative options.

Clinical evidence demonstrates that Wegovy produces significant weight loss when combined with lifestyle modification. The STEP clinical trial programme showed average weight loss of 12–15% of body weight over 68 weeks, compared to 2–3% with placebo (STEP 1, NEJM 2021).^[11] For a person weighing 100 kg, this translates to 12–15 kg weight loss. Note that weight loss may be lower in people with type 2 diabetes. Importantly, trials also demonstrated improvements in cardiovascular risk factors, glycaemic control in people with type 2 diabetes, and quality of life measures. However, weight regain commonly occurs if treatment is discontinued, meaning long-term use may be necessary to maintain benefits.^[13]

Cost-effectiveness from a personal perspective depends on:

• Health impact: Whether weight loss improves or resolves comorbidities (potentially reducing other medication costs)

• Alternative options: Comparative costs and effectiveness of other weight management approaches

• Sustainability: Ability to afford long-term treatment (potentially years)

• Individual response: Not everyone achieves the average weight loss seen in trials

NICE guidance recommends discontinuing Wegovy if less than 5% weight loss is achieved after 6 months, as continued treatment is unlikely to provide sufficient benefit to justify the cost and potential adverse effects. NHS treatment is limited to a maximum of 2 years within specialist services.^[2][3]

Alternatives to consider include:

• Lifestyle modification programmes – often more affordable and sustainable long-term

• Other weight-loss medications – such as orlistat (available over-the-counter at lower cost) or liraglutide 3 mg

• Bariatric surgery – potentially more cost-effective for severe obesity with better long-term outcomes

When to contact your GP: Discuss Wegovy if you have obesity with weight-related health conditions, have struggled with conventional weight loss methods, and want to explore all available options. Your GP can advise on NHS referral pathways, assess suitability, and discuss whether the potential benefits justify the costs and commitment required for successful treatment.

If you experience side effects while taking Wegovy, report them to your healthcare provider and consider reporting suspected adverse reactions via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app).

Frequently Asked Questions